A number of these next-generation SERDs are currently being investigated in phase I–III clinical trials in early- and advanced-stage breast cancer, both alone and in combination with CDK4/6 inhibitors (ClinicalTrials.gov identifiers NCT04647487, NCT03455270, NCT04669587 and NCT04711252). This evidence concerns the gene CDK4 and breast carcinoma.